View Clinical Trial (Medical Research Study)

Predictors of Cognitive Decline in Normal Aging - NCT00094939-10016(Clinical Trial 122293)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New York City
State:  
NY
Zip Code: 10016
Conditions: Alzheimer Disease - Dementia
Purpose: The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD) by monitoring loss of neurons and brain size reductions over a period of five years.
Study summary: Studies of normal aging and mild cognitive impairment (MCI) show that loss of neurons and reduction in size of the hippocampal part of the brain predict a person's conversion from MCI to Alzheimer's disease (AD). Increases in tangle-related abnormal tau proteins, specifically P-tau231, also appear to be related. This study will collect neuropsychological data, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) from volunteer participants to measure the relationship between changes in brain volume, CSF levels, and memory performance. From the data researchers hope to develop an early diagnostic test for AD. The study will include 170 participants between the ages of 60 and 80 years, some normal, some with MCI, some with mild AD, and some with frontotemporal dementia. After initial screening of volunteers, the researchers will give participants a complete baseline exam and 24-month follow-up exams over a period of five years.
Criteria: Inclusion Criteria: - Males and females, from all racial and ethnic categories between the ages of 60-80 years of age, with English as their first language. - Residents of the New York City metropolitan area. - Minimum of 12 years of education. - Participants will be grouped according to the following classifications: normal aging, mild cognitive impairment (MCI), Alzheimer's disease (AD), or frontotemporal dementia (FTD). - Participants will agree to ApoE genotyping and DNA banking. Exclusion Criteria: - Past history or MRI evidence of brain damage including significant trauma, stroke, hydrocephalus, lacunar infarcts, seizures, mental retardation or serious neurological disorder. - Significant history of alcoholism or drug abuse. - History of psychiatric illness (e.g., schizophrenia, mania or depression). - Any focal signs or significant neuropathology. - A score of 4 or greater on the Modified Hachinski Ischemia Scale suggesting cerebrovascular disease. - A total score of 16 or more on the Hamilton Depression Scale to exclude possible cases of primary depression. - Evidence of clinically relevant and uncontrolled hypertensive, cardiac, pulmonary, vascular, metabolic or hematologic conditions. - Physical impairment of such severity as to adversely affect the validity of psychological testing. - Hostility or refusal to cooperate. - Any prosthetic devices (e.g., pacemaker or surgical clips) that could be affected by the magnetic field employed during MRI imaging. - History of familial early onset dementia.
Study is available at: Center for Brain Health, Silberstein Institute, New York University School of Medicine
New York City, NY 10016
United States

Primary Contact:
Kenneth E. Rich
Email: kenneth.rich@med.nyu.edu
Phone: 212-263-7563

Secondary Contact:
Kenneth E. Rich
Email: kenneth.rich@med.nyu.edu
Phone: 212-263-7563
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 21, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.